Identification

Name
Salicylic acid
Accession Number
DB00936  (APRD01605, DB01398)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A compound obtained from the bark of the white willow and wintergreen leaves, and also prepared synthetically. It has bacteriostatic, fungicidal, and keratolytic actions. Its salts, the salicylates, are used as analgesics.

Structure
Thumb
Synonyms
  • 2-Carboxyphenol
  • 2-Hydroxybenzoic acid
  • O-carboxyphenol
  • O-hydroxybenzoic acid
External IDs
FEMA NO. 3985 / K-557 / NSC-180
Product Ingredients
IngredientUNIICASInChI Key
Choline magnesium trisalicylateNot Available64425-90-7FQCQGOZEWWPOKI-UHFFFAOYSA-K
Potassium salicylateK91YT16P5M578-36-9FRMWBRPWYBNAFB-UHFFFAOYSA-M
Sodium salicylateWIQ1H85SYP54-21-7ABBQHOQBGMUPJH-UHFFFAOYSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bioelements Active AstringentLiquid.5 mL/100mLTopicalBioelements2009-01-01Not applicableUs
Clearasil CompleteLotion2 %TopicalProcter And GambleNot applicableNot applicableCanada
Clearasil Stayclear Acne Defense CleanserLotion2 %TopicalProcter And GambleNot applicableNot applicableCanada
Clearasil Stayclear Zone Control ClearstickLiquid2 %TopicalProcter And GambleNot applicableNot applicableCanada
Dhs SalShampoo3.0 %TopicalSeaford Pharmaceuticals IncNot applicableNot applicableCanada
Exorex Acne FormulaLotion0.5 %TopicalMeyer Zall Laboratories Pty Ltd.Not applicableNot applicableCanada
Saliject 570mg/mlLiquid570 mgIntravenousOmega Laboratories Ltd1985-12-31Not applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
24 Hour Pimple PunisherKitKate Somerville Skincare Llc2014-06-22Not applicableUs
28 Remedy Acne Pore Deep CleanserGel.6 g/120mLTopicalNo Ts Co.,Ltd2016-01-02Not applicableUs
3 Part Acne Treatment Kit Ceela NaturaalsKitCeela Naturals, Llc2017-10-09Not applicableUs
Acence Tea Tree Tock Blemish SpotSolution22.5 mg/15mLTopicalMizon Co., Ltd.2015-12-01Not applicableUs
AcneLiquid1.2 g/240mLTopicalGreat Lakes Wholesale, Marketing, and Sales, Inc.2016-06-30Not applicableUs
AcneCream14 g/100gTopicalGreenbrier International, Inc.2013-01-01Not applicableUs
Acne and Blemish TargetGel2 g/100gTopicalBiocosmetics Research Labs2003-02-13Not applicableUs
Acne and Line Correcting SerumLotion10 mg/mLTopicalClinique Laboratories, Inc.2016-08-15Not applicableUs
Acne and Oil ControlGel2 g/100mLTopicalSkin Authority Llc2012-04-19Not applicableUs
Acne Beauty Benefit LightCream.5 g/100gTopicalGreenbrier International, Inc.2015-05-05Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
28 Remedy Balancing Toner 10mLCream.001 mg/10mLTopicalNo Ts Co.,Ltd2015-09-01Not applicableUs
AC Out Spot stOp SerumLiquid.1 mg/100mLTopicalThe Doctors Cosmetics Co., Ltd2012-09-27Not applicableUs
Ac7Gel.000001 g/10mLTopicalMicell Korea Co.,ltd2017-03-20Not applicableUs
AliclenShampoo60 mg/mLTopicalPrasco, Laboratories2011-02-022016-10-26Us
Bensal HPOintment30 mg/gTopicalSmg Pharmaceuticals, Llc1998-10-01Not applicableUs
Biore Baking Soda Acne Cleansing FoamGel.5 g/100mLTopicalKao Corporation2017-11-16Not applicableUs
Blackhead Clearing ScrubGel19.4 mg/gTopicalVi Jon2007-08-13Not applicableUs
Body WashGel25 mg/mLTopicalVi Jon2015-01-15Not applicableUs
Carahen hair-loss recoveryShampoo.3 g/100mLTopicalB.n.trinity Co.,ltd2017-07-20Not applicableUs
Carahen scalp revitalizing serum mistLiquid.2 g/100mLTopicalB.n.trinity Co.,ltd2017-07-20Not applicableUs
International/Other Brands
Compound W / Dr. Scholl's Callus Removers / Dr. Scholl's Corn Removers / Dr. Scholl's Wart Remover Kit / Duofil Wart Remover / Duoplant / Ionil Plus shampoo / Salonil / Salsonin / Stridex
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acne Clearning Treatment FaceSalicylic acid (.0048 mg/.024mg) + Benzoyl peroxide (.006 mg/.024mg) + Sulfur (.012 mg/.024mg)LiquidTopicalCare Pluss Pharma S.A. De C.V.2012-08-06Not applicableUs
Acne Treatment SystemSalicylic acid (2 %) + Benzoyl peroxide (5 %)Kit; Liquid; LotionTopicalVivier Canada Incorporated2013-11-15Not applicableCanada
Acne Treatment SystemSalicylic acid + Benzoyl peroxideKitVivier Pharma2017-07-19Not applicableUs
ActikerallSalicylic acid (10 %) + Fluorouracil (0.5 %)SolutionTopicalCipher Pharmaceuticals Inc.2016-02-19Not applicableCanada
Adasept Acne GelSalicylic acid (2 %) + Sodium thiosulfate (8 %) + Triclosan (0.5 %)LotionTopicalOdan Laboratories Ltd1974-12-31Not applicableCanada
Add More HairSalicylic acid (.2 g/100mL) + Dexpanthenol (.5 g/100mL) + Pyrithione zinc (.29 g/100mL)ShampooTopicalMyung Sung Co., Ltd.2017-03-01Not applicableUs
Advance Acne CareSalicylic acid + SilverKitTopicalSwabplus Inc.2008-08-07Not applicableUs
Anti-acne Formula for MenSalicylic acid (1 %) + Sulfur (3.75 %)CreamTopicalClinique Laboratories Dist1987-12-311998-08-26Canada
Anti-acne Formula-lightSalicylic acid (1 %) + Sulfur (3.75 %)CreamTopicalClinique Laboratories Dist1986-12-311996-09-09Canada
Anti-acne Formula-mediumSalicylic acid (1 %) + Sulfur (3.75 %)CreamTopicalClinique Laboratories Dist1986-12-311996-09-09Canada
Categories
UNII
O414PZ4LPZ
CAS number
69-72-7
Weight
Average: 138.1207
Monoisotopic: 138.031694058
Chemical Formula
C7H6O3
InChI Key
YGSDEFSMJLZEOE-UHFFFAOYSA-N
InChI
InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)
IUPAC Name
2-hydroxybenzoic acid
SMILES
OC(=O)C1=CC=CC=C1O

Pharmacology

Indication

Key additive in many skin-care products for the treatment of acne, psoriasis, callouses, corns, keratosis pilaris and warts.

Structured Indications
Pharmacodynamics

Salicylic acid treats acne by causing skin cells to slough off more readily, preventing pores from clogging up. This effect on skin cells also makes salicylic acid an active ingredient in several shampoos meant to treat dandruff. Use of straight salicylic solution may cause hyperpigmentation on unpretreated skin for those with darker skin types (Fitzpatrick phototypes IV, V, VI), as well as with the lack of use of a broad spectrum sunblock. Subsalicylate in combination with bismuth form the popular stomach relief aid known commonly as Pepto-Bismol. When combined the two key ingredients help control diarrhea, nausea, heartburn, and even gas. It is also very mildly anti-biotic.

Mechanism of action

Salicylic acid directly and irreversibly inhibits the activity of both types of cyclo-oxygenases (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Salicylate may competitively inhibit prostaglandin formation. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms. Salicylic acid is a key ingredient in many skin-care products for the treatment of acne, psoriasis, calluses, corns, keratosis pilaris, and warts. It works by causing the cells of the epidermis to slough off more readily, preventing pores from clogging up, and allowing room for new cell growth. Because of its effect on skin cells, salicylic acid is used in several shampoos used to treat dandruff. Salicylic acid is also used as an active ingredient in gels which remove verrucas (plantar warts). Salicylic acid inhibits the oxidation of uridine-5-diphosphoglucose (UDPG) competitively with nicotinamide adenosine dinucleotide (NAD) and noncompetitively with UDPG. It also competitively inhibits the transferring of glucuronyl group of uridine-5-phosphoglucuronic acid (UDPGA) to the phenolic acceptor. The wound-healing retardation action of salicylates is probably due mainly to its inhibitory action on mucopolysaccharide synthesis.

TargetActionsOrganism
AProstaglandin G/H synthase 1
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
UAldo-keto reductase family 1 member C1
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Oral rat LD50: 891 mg/kg. Inhalation rat LC50: > 900 mg/m3/1hr. Irritation: skin rabbit: 500 mg/24H mild. Eye rabbit: 100 mg severe. Investigated a mutagen and reproductive effector.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Salicylic Acid Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Salicylic acid.Approved
AbirateroneThe metabolism of Salicylic acid can be decreased when combined with Abiraterone.Approved
AcarboseSalicylic acid may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololSalicylic acid may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolSalicylic acid may increase the anticoagulant activities of Acenocoumarol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Salicylic acid.Approved, Vet Approved
AclarubicinSalicylic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Salicylic acid.Approved
AlbiglutideSalicylic acid may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Alendronic acid.Approved
AliskirenSalicylic acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Alminoprofen.Experimental
AlogliptinSalicylic acid may increase the hypoglycemic activities of Alogliptin.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Aloxiprin.Experimental
AlprenololSalicylic acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Salicylic acid.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Alteplase.Approved
ALX-0081The risk or severity of adverse effects can be increased when Salicylic acid is combined with ALX-0081.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Amcinonide.Approved
AmikacinSalicylic acid may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideSalicylic acid may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidSalicylic acid may increase the anticoagulant activities of Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Salicylic acid can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Amlodipine.Approved
Ammonium chlorideThe serum concentration of Salicylic acid can be increased when it is combined with Ammonium chloride.Approved, Vet Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Salicylic acid.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Amrinone.Approved
AmrubicinSalicylic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Salicylic acid.Approved
AncrodSalicylic acid may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Anisodamine.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Anistreplase.Approved
annamycinSalicylic acid may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Antipyrine.Approved
Antithrombin III humanSalicylic acid may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanSalicylic acid may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Apocynin.Investigational
ApramycinSalicylic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Salicylic acid can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinSalicylic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinSalicylic acid may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Salicylic acid.Approved, Investigational
ArotinololSalicylic acid may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AstaxanthinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Atamestane.Investigational
AtenololSalicylic acid may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Salicylic acid.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salicylic acid.Approved
AzimilideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Azimilide.Investigational
BalsalazideSalicylic acid may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Barnidipine.Approved
BatroxobinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Batroxobin.Experimental
BecaplerminSalicylic acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololSalicylic acid may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinSalicylic acid may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bemiparin.Approved, Investigational
BenazeprilSalicylic acid may decrease the antihypertensive activities of Benazepril.Approved, Investigational
BencyclaneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bencyclane.Experimental
BendazacThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salicylic acid.Approved
BenidipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Benidipine.Approved, Investigational
BenorilateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Benzydamine.Approved
BepridilThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bepridil.Approved, Withdrawn
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Salicylic acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Betamethasone.Approved, Vet Approved
BetaxololSalicylic acid may decrease the antihypertensive activities of Betaxolol.Approved
BevantololSalicylic acid may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Salicylic acid.Approved, Investigational
BisoprololSalicylic acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinSalicylic acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololSalicylic acid may decrease the antihypertensive activities of Bopindolol.Approved
BrinaseThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Brinzolamide.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Salicylic acid.Approved
BromocriptineSalicylic acid may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bucillamine.Investigational
BucindololSalicylic acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bufexamac.Experimental
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Salicylic acid.Experimental
BufuralolSalicylic acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bumadizone.Experimental
BumetanideSalicylic acid may decrease the diuretic activities of Bumetanide.Approved
BupranololSalicylic acid may decrease the antihypertensive activities of Bupranolol.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Salicylic acid.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Salicylic acid.Approved, Investigational
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Salicylic acid.Investigational
CanagliflozinSalicylic acid may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Salicylic acid.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Salicylic acid.Approved
CandoxatrilSalicylic acid may decrease the antihypertensive activities of Candoxatril.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Salicylic acid.Approved
CapecitabineThe metabolism of Salicylic acid can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilSalicylic acid may decrease the antihypertensive activities of Captopril.Approved
CarbamazepineThe metabolism of Salicylic acid can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Salicylic acid.Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Caroverine.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Salicylic acid.Approved, Vet Approved, Withdrawn
CarteololSalicylic acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolSalicylic acid may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Salicylic acid.Approved, Investigational
CeliprololSalicylic acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Salicylic acid can be increased when it is combined with Ceritinib.Approved
CertoparinSalicylic acid may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Salicylic acid.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
ChlorpropamideSalicylic acid may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salicylic acid.Approved
CholecalciferolThe metabolism of Salicylic acid can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Salicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ciclesonide.Approved, Investigational
CilazaprilSalicylic acid may decrease the antihypertensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Cilnidipine.Approved, Investigational
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Salicylic acid.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Cinnarizine.Approved, Investigational
CinoxacinSalicylic acid may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Salicylic acid.Approved, Investigational, Withdrawn
Citric AcidSalicylic acid may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clevidipine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clonixin.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Salicylic acid.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Salicylic acid.Vet Approved
CloranololSalicylic acid may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Salicylic acid.Experimental
ClorindioneSalicylic acid may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Salicylic acid can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Salicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Salicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Salicylic acid.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Salicylic acid can be decreased when combined with Crisaborole.Approved
CurcuminThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Salicylic acid.Experimental
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Salicylic acid.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with D-Limonene.Investigational
Dabigatran etexilateSalicylic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Salicylic acid can be decreased when it is combined with Dabrafenib.Approved
DalteparinSalicylic acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSalicylic acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinSalicylic acid may increase the hypoglycemic activities of Dapagliflozin.Approved
DarexabanSalicylic acid may increase the anticoagulant activities of Darexaban.Investigational
DarodipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Darodipine.Experimental
DaunorubicinSalicylic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Salicylic acid.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Deflazacort.Approved
DelaprilSalicylic acid may decrease the antihypertensive activities of Delapril.Experimental
DelavirdineThe metabolism of Salicylic acid can be decreased when combined with Delavirdine.Approved
dersalazineSalicylic acid may increase the anticoagulant activities of dersalazine.Investigational
DesirudinSalicylic acid may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Dexketoprofen.Approved, Investigational
DextranSalicylic acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Salicylic acid may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Salicylic acid may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Salicylic acid may increase the anticoagulant activities of Dextran 75.Approved
DibekacinSalicylic acid may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Salicylic acid.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Diclofenamide.Approved
DicoumarolSalicylic acid may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineDidanosine can cause a decrease in the absorption of Salicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salicylic acid.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Salicylic acid.Approved
DihydrostreptomycinSalicylic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Salicylic acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Salicylic acid.Approved
DiphenadioneSalicylic acid may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Salicylic acid.Approved
DisopyramideSalicylic acid may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ditazole.Approved, Withdrawn
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Salicylic acid.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Salicylic acid.Approved
DorzolamideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Dorzolamide.Approved
DosulepinThe metabolism of Salicylic acid can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Dotarizine.Investigational
DoxorubicinSalicylic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneSalicylic acid may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Droxicam.Approved
DulaglutideSalicylic acid may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Salicylic acid is combined with E-6201.Investigational
Edetic AcidSalicylic acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSalicylic acid may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Salicylic acid can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Efonidipine.Approved, Investigational
EmpagliflozinSalicylic acid may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilSalicylic acid may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
EnalaprilatSalicylic acid may decrease the antihypertensive activities of Enalaprilat.Approved
EnoxacinSalicylic acid may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinSalicylic acid may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Salicylic acid.Experimental
EpanololSalicylic acid may decrease the antihypertensive activities of Epanolol.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Salicylic acid.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Epirizole.Approved
EpirubicinSalicylic acid may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneSalicylic acid may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Salicylic acid.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Salicylic acid.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Salicylic acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salicylic acid.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Salicylic acid.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Equilin.Approved
EsmololSalicylic acid may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Estrone sulfate.Approved
Etacrynic acidSalicylic acid may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Salicylic acid.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ethenzamide.Experimental
EthoxzolamideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateSalicylic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Salicylic acid.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Salicylic acid.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Evening primrose oil.Approved, Investigational
ExenatideSalicylic acid may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Salicylic acid is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fenbufen.Approved
FendilineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fendiline.Withdrawn
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Salicylic acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Salicylic acid.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Feprazone.Experimental
Ferulic acidSalicylic acid may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Salicylic acid.Approved, Investigational
FleroxacinSalicylic acid may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Salicylic acid.Approved, Withdrawn
FloxuridineThe metabolism of Salicylic acid can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with fluasterone.Investigational
FluconazoleThe metabolism of Salicylic acid can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fludrocortisone.Approved
FluindioneSalicylic acid may increase the anticoagulant activities of Fluindione.Investigational
FlumequineSalicylic acid may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Flumethasone.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Flunarizine.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Salicylic acid can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Salicylic acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salicylic acid.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Salicylic acid can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Salicylic acid can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Salicylic acid.Approved, Nutraceutical, Vet Approved
FondaparinuxSalicylic acid may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumSalicylic acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Salicylic acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilSalicylic acid may decrease the antihypertensive activities of Fosinopril.Approved
FosphenytoinThe serum concentration of Salicylic acid can be decreased when it is combined with Fosphenytoin.Approved
FramycetinSalicylic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideSalicylic acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Gabapentin.Approved, Investigational
GabexateSalicylic acid may increase the anticoagulant activities of Gabexate.Investigational
GallopamilThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Gallopamil.Investigational
GarenoxacinSalicylic acid may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSalicylic acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Salicylic acid.Approved, Withdrawn
GemfibrozilThe metabolism of Salicylic acid can be decreased when combined with Gemfibrozil.Approved
GemifloxacinSalicylic acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinSalicylic acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinSalicylic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ASalicylic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Salicylic acid.Approved, Investigational, Nutraceutical
GliclazideSalicylic acid may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideSalicylic acid may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideSalicylic acid may increase the hypoglycemic activities of Glipizide.Approved
GlyburideSalicylic acid may increase the hypoglycemic activities of Glyburide.Approved
GPX-150Salicylic acid may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinSalicylic acid may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Salicylic acid is combined with HE3286.Investigational
Hemoglobin crosfumarilSalicylic acid may increase the anticoagulant activities of Hemoglobin crosfumaril.Experimental
HeparinSalicylic acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Salicylic acid.Approved, Investigational
HydralazineSalicylic acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salicylic acid.Approved, Investigational
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Salicylic acid.Investigational
Hygromycin BSalicylic acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ibandronate.Approved, Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Salicylic acid.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Icatibant.Approved
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Salicylic acid.Approved, Nutraceutical
IdarubicinSalicylic acid may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxSalicylic acid may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Salicylic acid.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Salicylic acid.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Salicylic acid.Approved, Investigational
ImidaprilSalicylic acid may decrease the antihypertensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylic acid.Approved
IndenololSalicylic acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Salicylic acid can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salicylic acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Indoprofen.Withdrawn
INNO-206Salicylic acid may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
Insulin AspartSalicylic acid may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirSalicylic acid may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineSalicylic acid may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineSalicylic acid may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanSalicylic acid may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproSalicylic acid may increase the hypoglycemic activities of Insulin Lispro.Approved
IrbesartanThe metabolism of Salicylic acid can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinSalicylic acid may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Isoxicam.Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Istaroxime.Investigational
KanamycinSalicylic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Kebuzone.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Salicylic acid.Investigational
KetoconazoleThe metabolism of Salicylic acid can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Salicylic acid.Approved
LabetalolSalicylic acid may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lamotrigine.Approved, Investigational
LandiololSalicylic acid may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Salicylic acid.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Salicylic acid.Approved, Investigational
LeflunomideThe metabolism of Salicylic acid can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinSalicylic acid may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lercanidipine.Approved, Investigational
LetaxabanSalicylic acid may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololSalicylic acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSalicylic acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LidoflazineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lidoflazine.Experimental
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Salicylic acid.Approved, Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Salicylic acid.Experimental
LiraglutideSalicylic acid may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilSalicylic acid may decrease the antihypertensive activities of Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Salicylic acid.Approved
LobeglitazoneThe metabolism of Salicylic acid can be decreased when combined with Lobeglitazone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lornoxicam.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Salicylic acid.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Loteprednol.Approved
LovastatinThe metabolism of Salicylic acid can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Salicylic acid.Approved, Investigational
LumacaftorThe serum concentration of Salicylic acid can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Salicylic acid.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Salicylic acid.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Salicylic acid is combined with ME-609.Investigational
MecaserminSalicylic acid may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salicylic acid.Approved
MelagatranSalicylic acid may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Salicylic acid.Approved, Vet Approved
MepindololSalicylic acid may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineSalicylic acid may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Metamizole.Investigational, Withdrawn
MetforminSalicylic acid may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Salicylic acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylic acid.Approved
Methyl salicylateSalicylic acid may increase the anticoagulant activities of Methyl salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Methylprednisolone.Approved, Vet Approved
MetipranololSalicylic acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylic acid.Approved
MetoprololSalicylic acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideSalicylic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MibefradilThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Mibefradil.Investigational, Withdrawn
MicronomicinSalicylic acid may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Salicylic acid can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Salicylic acid can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolSalicylic acid may increase the hypoglycemic activities of Miglitol.Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Salicylic acid.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Salicylic acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Mizoribine.Investigational
MoexiprilSalicylic acid may decrease the antihypertensive activities of Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Salicylic acid.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salicylic acid.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Salicylic acid.Approved
NadololSalicylic acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinSalicylic acid may increase the anticoagulant activities of Nadroparin.Approved
NafamostatSalicylic acid may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Salicylic acid.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Naftopidil.Investigational
Nalidixic AcidSalicylic acid may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Salicylic acid.Approved, Vet Approved
NateglinideSalicylic acid may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Salicylic acid is combined with NCX 1022.Investigational
NeamineSalicylic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololSalicylic acid may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinSalicylic acid may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinSalicylic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Salicylic acid.Approved
NetilmicinSalicylic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe metabolism of Salicylic acid can be decreased when combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Niflumic Acid.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Niguldipine.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nitrendipine.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Salicylic acid.Investigational
NorfloxacinSalicylic acid may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Salicylic acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salicylic acid.Approved
OlsalazineSalicylic acid may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatSalicylic acid may decrease the antihypertensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Salicylic acid can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Orgotein.Vet Approved
OtamixabanSalicylic acid may increase the anticoagulant activities of Otamixaban.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Otilonium.Experimental, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Oxaprozin.Approved
Oxolinic acidSalicylic acid may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololSalicylic acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Oxyphenbutazone.Approved, Withdrawn
OzagrelThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ozagrel.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Parecoxib.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Parnaparin.Approved, Investigational
ParomomycinSalicylic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Parthenolide.Investigational
PazufloxacinSalicylic acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSalicylic acid may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololSalicylic acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateSalicylic acid may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineSalicylic acid may increase the hypoglycemic activities of Pentamidine.Approved
Pentosan PolysulfateSalicylic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Salicylic acid.Approved, Investigational
PerhexilineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Perhexiline.Approved, Investigational
PerindoprilSalicylic acid may decrease the antihypertensive activities of Perindopril.Approved
PhenindioneSalicylic acid may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Salicylic acid can be increased when combined with Phenobarbital.Approved
PhenprocoumonSalicylic acid may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Salicylic acid.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Salicylic acid.Approved, Vet Approved
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Salicylic acid.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salicylic acid.Approved, Investigational
PimozideSalicylic acid may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pinaverium.Approved
PindololSalicylic acid may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneSalicylic acid may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
Pipemidic acidSalicylic acid may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinSalicylic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideSalicylic acid may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pirfenidone.Approved, Investigational
Piromidic acidSalicylic acid may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salicylic acid.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pirprofen.Experimental
Platelet Activating FactorSalicylic acid may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinSalicylic acid may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinSalicylic acid may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Salicylic acid.Approved
PractololSalicylic acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Salicylic acid.Approved
PramlintideSalicylic acid may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prasterone sulfate.Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Salicylic acid.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pregabalin.Approved, Illicit, Investigational
PregnenoloneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pregnenolone.Experimental, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prenylamine.Withdrawn
PrimidoneThe metabolism of Salicylic acid can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Salicylic acid.Approved
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Propacetamol.Approved, Investigational
PropranololSalicylic acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Salicylic acid.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Salicylic acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Salicylic acid.Vet Approved
Protein CSalicylic acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanSalicylic acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSalicylic acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinSalicylic acid may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Salicylic acid is combined with PTC299.Investigational
PuromycinSalicylic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Salicylic acid can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilSalicylic acid may decrease the antihypertensive activities of Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Salicylic acid.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Salicylic acid.Approved
QuinineThe metabolism of Salicylic acid can be decreased when combined with Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Salicylic acid.Investigational
RamiprilSalicylic acid may decrease the antihypertensive activities of Ramipril.Approved
RanolazineThe serum concentration of Salicylic acid can be increased when it is combined with Ranolazine.Approved, Investigational
RepaglinideSalicylic acid may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineSalicylic acid may decrease the antihypertensive activities of Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Salicylic acid.Approved, Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Reteplase.Approved
ReviparinSalicylic acid may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinSalicylic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Salicylic acid.Approved
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Salicylic acid.Approved
RifampicinThe metabolism of Salicylic acid can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Salicylic acid can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Salicylic acid.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Risedronate.Approved, Investigational
RivaroxabanSalicylic acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Salicylic acid.Investigational, Withdrawn
RosiglitazoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Rosiglitazone.Approved, Investigational
RosoxacinSalicylic acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinSalicylic acid may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinSalicylic acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Salicylic acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Salicylamide.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salicylic acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Salicylic acid.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Salicylic acid.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Saruplase.Experimental
SaxagliptinSalicylic acid may increase the hypoglycemic activities of Saxagliptin.Approved
SecobarbitalThe metabolism of Salicylic acid can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Salicylic acid.Approved, Vet Approved
SildenafilThe metabolism of Salicylic acid can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinSalicylic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinSalicylic acid may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitagliptinSalicylic acid may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Salicylic acid.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Salicylic acid.Approved
SorafenibThe metabolism of Salicylic acid can be decreased when combined with Sorafenib.Approved, Investigational
SotalolSalicylic acid may decrease the antihypertensive activities of Sotalol.Approved
SP1049CSalicylic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinSalicylic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinSalicylic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilSalicylic acid may decrease the antihypertensive activities of Spirapril.Approved
SpironolactoneSalicylic acid may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Salicylic acid.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Streptokinase.Approved, Investigational
StreptomycinSalicylic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinSalicylic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SucralfateSucralfate can cause a decrease in the absorption of Salicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfadiazineThe metabolism of Salicylic acid can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Salicylic acid can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Salicylic acid.Approved
SulfisoxazoleThe metabolism of Salicylic acid can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Salicylic acid.Approved
SulodexideSalicylic acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Salicylic acid.Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Salicylic acid.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Salicylic acid.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Suxibuzone.Experimental
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Salicylic acid.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Salicylic acid.Approved
TalinololSalicylic acid may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Salicylic acid.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Salicylic acid.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salicylic acid.Approved, Investigational
TemafloxacinSalicylic acid may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilSalicylic acid may decrease the antihypertensive activities of Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Salicylic acid.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Teriflunomide.Approved
TerodilineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Terodiline.Experimental
TertatololSalicylic acid may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Salicylic acid.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tetrahydropalmatine.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tiaprofenic acid.Approved
TicagrelorThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Salicylic acid.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Salicylic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololSalicylic acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tinoridine.Investigational
TinzaparinThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tinzaparin.Approved
TioclomarolSalicylic acid may increase the anticoagulant activities of Tioclomarol.Experimental
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Salicylic acid.Approved
TixocortolThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tixocortol.Approved
TobramycinSalicylic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolazamideSalicylic acid may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideThe metabolism of Salicylic acid can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salicylic acid.Approved
TopiroxostatThe metabolism of Salicylic acid can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideSalicylic acid may decrease the diuretic activities of Torasemide.Approved
TrandolaprilSalicylic acid may decrease the antihypertensive activities of Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tranilast.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Salicylic acid.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salicylic acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salicylic acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneSalicylic acid may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Salicylic acid.Approved, Investigational
TrimethoprimThe metabolism of Salicylic acid can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Triptolide.Investigational
Trolamine salicylateSalicylic acid may increase the anticoagulant activities of Trolamine salicylate.Approved
TrovafloxacinSalicylic acid may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinSalicylic acid may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Salicylic acid.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Salicylic acid.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Salicylic acid.Approved, Investigational
ValrubicinSalicylic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Salicylic acid can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Salicylic acid.Approved
VerapamilThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Verapamil.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Vinpocetine.Investigational
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Salicylic acid.Approved
VoriconazoleThe metabolism of Salicylic acid can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinSalicylic acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSalicylic acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Xylometazoline.Approved
ZafirlukastThe metabolism of Salicylic acid can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Zaltoprofen.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ziconotide.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Salicylic acid.Approved, Investigational, Withdrawn
ZofenoprilSalicylic acid may decrease the antihypertensive activities of Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Zoledronic acid.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Salicylic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinSalicylic acid may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinSalicylic acid may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Howard Jones, Robert W. Houser, "Process for preparing 4-(2,4-difluorophenyl)-salicyclic acid." U.S. Patent US4225730, issued August, 1972.

US4225730
General References
  1. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5. [PubMed:5284360]
  2. Flower R, Gryglewski R, Herbaczynska-Cedro K, Vane JR: Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat New Biol. 1972 Jul 26;238(82):104-6. [PubMed:4505422]
External Links
Human Metabolome Database
HMDB01895
KEGG Drug
D00097
KEGG Compound
C00805
PubChem Compound
338
PubChem Substance
46504942
ChemSpider
331
BindingDB
26193
ChEBI
16914
ChEMBL
CHEMBL424
Therapeutic Targets Database
DAP000731
PharmGKB
PA451299
IUPHAR
4306
Guide to Pharmacology
GtP Drug Page
HET
SAL
Wikipedia
Salicylic_acid
ATC Codes
N02BA04 — Sodium salicylateD01AE12 — Salicylic acidS01BC08 — Salicylic acidN02BA12 — Potassium salicylate
AHFS Codes
  • 84:28.00 — Keratolytic Agents
  • 28:08.04.24 — Salicylates
  • 24:16.00 — Sclerosing Agents
PDB Entries
1fiq / 1fo4 / 1jgs / 1m6e / 1pth / 1wyg / 1y7i / 2e1q / 2fn1 / 2i2z
show 36 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentGamma Delta Hepatosplenic T-Cell Lymphoma / NK T-Cell Lymphoma / Subcutaneous Panniculitis-Like T-Cell Lymphoma / T-Cell Peripheral Lymphoma1
1CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1TerminatedTreatmentLeukemias1
1, 2CompletedTreatmentAcne Vulgaris1
2Active Not RecruitingTreatmentLymphoma, Extranodal NK-T-Cell / T-Cell Lymphomas1
2Active Not RecruitingTreatmentLymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
2CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentChronic Arsenic Poisoning1
2CompletedTreatmentLymphoma, AIDS Related1
2CompletedTreatmentScalp Psoriasis1
2RecruitingTreatmentAnaplastic Large-Cell Lymphoma / Burkitt's Lymphoma / Gray Zone Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Primary mediastinal large B-cell lymphomas / Primary Meidastinal Lymphoma1
2RecruitingTreatmentLymphoma, AIDS Related / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentLymphomatoid Granulomatosis / Lymphoproliferative Disorders / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentLeukemias1
2, 3Unknown StatusTreatmentPlantar Warts1
3CompletedTreatmentActinic Keratosis (AK)1
4CompletedTreatmentAcne2
4CompletedTreatmentAcne Prone Skin1
4CompletedTreatmentSkin Diseases1
4Unknown StatusTreatmentQuality of Life / Seborrheic Dermatitis1
4Unknown StatusTreatmentWarts1
Not AvailableCompletedTreatmentArsenical Keratosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
GelTopical.6 g/120mL
CreamTopical.001 mg/10mL
LiquidTopical.1 mg/100mL
GelTopical.000001 g/10mL
SolutionTopical22.5 mg/15mL
CreamTopical14 g/100g
LiquidTopical1.2 g/240mL
CreamTopical.5 g/100g
GelTopical7 mg/354mg
GelTopical.02158 g/100mL
LiquidTopical.02 g/1
LiquidTopical29.2 mg/1
GelTopical2 g/100g
LiquidTopical.75 mg/150mL
GelTopical0.5 %
GelTopical1.5 g/100mL
GelTopical21 mg/mL
GelTopical.01 g/g
CreamTopical.5 mg/mL
SolutionTopical.2 g/40g
LiquidTopical1.5 mL/100mL
SoapTopical2 g/100g
LotionTopical1 mL/100mL
CreamTopical1 mL/100mL
GelTopical.5 mL/100mL
LiquidTopical.5 g/.5mL
CreamTopical.5 g/100mL
GelTopical.005 mg/g
LiquidTopical.018 mg/mg
PatchTopical2 g/100mL
Kit; liquid; lotionTopical
LiquidTopical2 g/200mL
SwabTopical.5 g/100mL
SwabTopical.5 g/100g
SwabTopical5 mg/1000mg
SwabTopical5 mg/mL
LotionTopical.02 mL/mL
ClothTopical5 mg/1
SprayTopical2.84 g/142g
SolutionTopical20 mg/1
LotionTopical10 mg/mL
GelTopical.6 g/30mL
LotionTopical1 mg/mL
CreamTopical1.5 %
CreamCutaneous.3 mL/15mL
PatchTopical2 mg/100mg
PlasterTopical.4 1/1001
PlasterTopical40 1/1
Aerosol, foamTopical1.5 g/100g
ClothTopical2 g/1
ClothTopical2 g/101
ClothTopical2 g/301
ShampooTopical60 mg/mL
GelTopical.5 %
PowderTopical.6 mg/mL
LiquidTopical.01 g/mL
LiquidTopical1 mg/mL
PowderTopical0.6 %
StripTopical1.4 %
Liquid; swabTopical.5 %
LiquidTopical.5 %
LiquidTopical1 g/200mL
LotionTopical250 g/5g
ShampooTopical200 g/6g
CreamTopical50 g/g
CreamTopical.08 g/20mL
CreamTopical5 mg/g
ShampooTopical.2 g/100mL
LiquidTopical.1 g/100mL
GelTopical15 uL/mL
SwabTopical10 uL/mL
JellyTopical1 %
RinseTopical2 g/397g
ShampooTopical2 g/414g
DiscTopical20 mg/1
StickTopical2 g/100g
CreamTopical5 mL/100mL
ShampooTopical20 mg/mL
SprayTopical5 mg/mL
LotionTopical.75 mg/150mL
LotionTopical1.1 mL/100mL
ClothTopical20 mg/mL
ClothTopical.5 g/100g
CreamTopical.5 mL/100mL
LotionTopical2 mL/100mL
SoapTopical0.50 %
SoapTopical.5 g/100g
ClothTopical6 mg/1
SoapTopical.5 %
SoapTopical5 mg/g
LotionTopical0.7 %
JellyTopical
StickTopical
StickTopical2 %
LotionTopical1.5 %
LiquidTopical1.5 %
SwabTopical40 %
EmulsionTopical20 mg/mL
EmulsionTopical10 mg/g
LiquidTopical2.1 g/100mL
OintmentTopical30 mg/g
SolutionTopical.5 g/100mL
Kit
LotionTopical1 %
ShampooTopical.24 mg/355mL
SprayTopical2 mg/355mL
OintmentTopical2.8 g/140g
GelTopical1.8 %
CreamTopical2 mL/100mL
GelTopical2 mL/100mL
GelTopical1.27 g/127g
GelTopical2.5 g/127g
LiquidTopical4.3 g/200mL
LiquidTopical4.56 g/236mL
GelTopical2 g/200mL
GelTopical1.3 g/127g
LiquidTopical2.8 g/141g
LiquidTopical2.54 g/127g
GelTopical19.4 mg/g
RinseTopical.2 mg/100mg
LotionTopical.587 g/118mL
LotionTopical2 g/120mL
LotionTopical1.5 g/15mL
LotionTopical.6 g/200mL
LotionTopical.6 g/100mL
LotionTopical2 g/40mL
ClothTopical10 mg/1
StripTopical.03 mg/1
GelTopical.02 g/g
GelTopical25 mg/mL
GelTopical1.25 g/250mL
PowderTopical
GelTopical.4 g/20g
OintmentTopical5 g/g
PatchTopical.19 mg/1
PatchTopical11.9 mg/21
ShampooTopical.3 g/100mL
PlasterTopical40 %
LotionTopical.5 g/59g
LiquidTransdermal
CreamTopical20.6 mg/mL
LiquidOral500 mg/5mL
LiquidTopical10 mg/mL
CreamTopical.156 g/8.9mL
CreamTopical.28 g/14g
LiquidTopical.623 g/130mL
LiquidTopical.691 g/133mL
PasteTopical5 mg/g
SprayTopical2 g/118mL
SolutionTopical10 mg/mL
GelTopical2 g/151mL
GelTopical30 mg/mL
LotionTopical
CreamTopical50 mg/mL
LiquidTopical50 mg/mL
GelTopical1 g/100g
LotionTopical.5 g/100mL
KitTopical
CreamTopical.6 mL/60mL
LiquidTopical2.4 mL/240mL
ClothTopical283.5 mg/56.7g
LotionTopical.0053 g/100mL
LotionTopical.0091 g/100mL
LiquidTopical2.00 %
GelTopical2 %
SolutionTopical2 g/100g
SalveTopical20 mg/mL
LiquidTopical3.57 mg/mL
LotionTopical.01 g/g
LotionTopical7 mg/mL
SwabTopical2 g/100mL
SolutionTopical.03 g/1
SolutionTopical.01 g/1
SolutionTopical.015 g/1
LotionTopical1 g/100mL
SolutionTopical1 g/100mL
LiquidTopical2 %
LotionTopical150 mL/mL
SolutionTopical.02 g/1
GelTopical10 g/.2g
CreamTopical50 g/.5g
GelTopical18.4 mg/mL
CreamTopical10 mg/g
LiquidTopical5 mL/250mL
PasteTopical5 mg/mL
LotionTopical.6 mL/30mL
LiquidTopical300 mg/30g
CreamTopical1.5 mL/75mL
GelTopical.022 mL/1.1mL
LiquidTopical5 mg/mL
CreamTopical1 mL/50mL
GelTopical.375 mL/75mL
LotionTopical5 mg/mL
GelTopical5 mg/mL
GelTopical.3 mL/15mL
LiquidTopical.25 g/50mL
LiquidTopical20 mg/mL
SolutionTopical20 mg/mL
StickTopical2 g/2mL
SprayTopical2 %
LiquidTopical1 %
CreamTopical1 %
GelTopical1 %
PowderTopical.5 g/100g
GelTopical17 %
LiquidTopical150 mg/mL
LiquidTopical20 %
PlasterTopical4 mg/1
LiquidTopical30 %
CreamTopical2 1/100g
EmulsionTopical.24 mg/29.6mg
EmulsionTopical1.89 mg/237mg
PlasterTopical40 mg/1
OintmentTopical15 %
CreamTopical1 g/100g
GelTopical.3 mg/30mL
StickTopical.025 g/2.5g
GelTopical.1425 g/30mL
LiquidTopical2 mg/30mg
PatchTopical40 mg/1
SoapTopical20 mg/g
LiquidTopical3 g/100mL
LiquidTopical20.5 mg/mL
TabletOral
CreamTopical5.05 mg/mL
SolutionTopical2.4 mL/120mL
LotionTopical.015 g/g
LiquidTopical17.64 mg/mL
LiquidTopical18 mg/mL
LotionTopical.5 %
LiquidTopical20 mg/g
OintmentTopical20 mg/g
LotionTopical10 uL/mL
LiquidTopical7.08 mL/236mL
LotionTopical2.36 mL/118mL
GelTopical3 %
GelTopical3.54 mL/118mL
CreamTopical3 g/100g
LiquidTopical.5 g/100g
LiquidTopical50.5 mg/2.5mL
LotionTopical30 mg/1.5mL
ShampooTopical3.0 %
SoapTopical4.8 g/240g
OintmentTopical
LiquidTopical25 g/100mL
TabletOral325 mg
TabletOral500 mg
GelTopical1 g/50mL
CreamTopical.01 g/15mL
SprayTopical.14 g/140mL
CreamTopical1.5 g/50mL
GelTopical.1 g/100mL
LiquidTopical.3 g/10mL
LiquidTopical12.64 %
SolutionTopical150 mg/mL
DiscTopical4 mg/1
SolutionTopical1.7 mg/mL
DiscTopical.4 g/1
LotionTopical20 mg/g
LiquidTopical.48 mL/100mL
LiquidCutaneous.5 mg/100mg
CreamCutaneous.5 mg/100mg
GelTopical11 %
LiquidTopical150.28 mg/mL
PatchTopical3 mg/30mL
PowderTopical1 g/100g
PasteTopical2 g/100g
LiquidTopical1 g/100g
StickTopical2 g/100mL
LotionTopical1 mg/g
GelTopical20 g/1000mL
Liquid, extended releaseTopical2 mg/100mL
PasteTopical20 mg/mL
SwabTopical21 mg/1
LiquidTopical170 mL/mL
LiquidTopical40 mg/1
GelTopical50 mg/mL
GelTopical.5 g/100mL
PatchTopical40 mg/100mg
LiquidTopical17 g/100mL
LiquidOral
SoapTopical2 %
CreamTopical2 %
LiquidTopical2.16 mg/120mL
LiquidTopical.2 g/100mL
OilTopical.01 mL/mL
GelTopical2000 mg/g
ShampooTopical11.52 mL/384mL
SolutionTopical15 mg/mL
SprayTopical20 mg/mL
SolutionTopical4.8 g/240mL
Aerosol, foamTopical.5 mL/100mL
LiquidTopical4 mL/200mL
GelTopical21.2 mg/100mL
LotionTopical3 g/100g
LiquidTopical3 g/100g
CreamTopical2 g/100g
GelTopical2.0 %
SolutionTopical1 mg/200mL
Lotion / shampooTopical18.5 mg/mL
ShampooTopical.1 1/300mL
LiquidTopical3 %
GelTopical
LotionTopical1.184 mL/59.2mL
LiquidTopical.003 mL/mL
LiquidTopical.0001 mL/mL
LotionTopical2.15 g/110mL
LiquidTopical1.2 g/120mL
SoapTopical1.35 g/135g
CreamTopical3 %
GelTopical2 mg/2mL
CreamTopical.5 mg/.5mL
LiquidTopical20 mL/L
LiquidTopical.02 mL/mL
GelTopical.02 mL/mL
ShampooTopical.5 g/100mL
CreamTopical0.5 %
JellyTopical.5 %
CreamTopical.5 %
GelTopical6 g/100g
ShampooTopical5 g/100mL
ShampooTopical6 g/92.6mL
GelTopical3 g/100g
GelTopical6 %
CreamTopical.15105 g/15mL
CreamTopical.025 mg/5mL
GelTopical5 mg/g
CreamTopical2 mCi/100mL
SolutionTopical5 mg/mL
LotionTopical.45 mL/30mL
PasteTopical
Cream; suspensionTopical0.5 %
SprayTopical4.72 mL/118mL
ClothTopical.6 mL/60mL
GelTopical.75 mL/50mL
GelTopical.425 mL/25mL
PasteTopical.75 mL/150mL
StickTopical36 mg/1.8g
SolutionTopical2 g/100mL
LiquidTopical.75 %
PlasterTopical.4 g/g
LiquidTopical17 mg/100mg
SwabTopical.02 mL/1
GelTopical19.8 mg/g
DiscTopical40 %
ShampooTopical1.8 g/100mL
PlasterTopical40 g/100g
PatchTopical.056 mg/1
PlasterTopical2.068 mg/1
PlasterTopical3.175 mg/1
PlasterTopical5.51 mg/1
ShampooTopical2 g
ShampooTopical.03 g/g
CreamTopical2.016 g/112g
LotionTopical30 mg/mL
SolutionTopical.15 mg/30mL
ClothTopical1 g/100g
ShampooTopical.2 1/300g
OintmentTopical40 %
SolutionTopical.1 g/25mL
LiquidTopical.06 g/mL
ShampooTopical.06 g/mL
EmulsionTopical1 g/100g
LiquidTopical.75 g/100g
CreamTopical30 mL/100mL
LiquidTopical1 mL/100mL
LotionTopical.5 mg/mL
ShampooTopical.01 g/100mL
SwabTopical2 mL/100mL
GelTopical1 mg/g
Aerosol, foamTopical20 mg/g
CreamTopical1 mg/g
SuspensionTopical20 mg/mL
Kit
Aerosol, foamTopical5 mg/g
LiquidTopical1.8 %
GelTopical20 mg/mL
ClothTopical20 mg/1
LotionTopical20 mg/mL
LotionTopical2.0 %
LiquidTopical5 mg/g
CreamTopical5.5 mg/g
GelTopical1.5 %
CreamTopical1.0 %
PowderTopical5 mg/g
ShampooTopical30 mg/mL
OintmentTopical2 g/100g
GelTopical3 mg/15mL
GelTopical.1 g/20mL
SoapTopical.01 g/g
ClothTopical.02 g/g
ClothTopical.05 mg/100mg
LotionTopical5 g/1000mL
GelTopical5 g/1000mL
Solution, gel forming / dropsTopical20 mg/mL
ShampooTopical9 mg/500g
LiquidTopical170 mg
ClothTopical20.5 mg/mL
LiquidTopical2.5 g/125g
LotionTopical20.6 mg/mL
GelTopical3 g/150g
GelTopical4 mg/177mg
CreamTopical.5 mL/50mL
GelTopical1.15 mL/115mL
GelTopical.06 mL/15mL
PatchTopical.4 g/g
SoapTopical.27 g/55g
SoapTopical.4 g/80g
SwabTopical20 mg/1
SwabTopical5 mg/1
SuspensionTopical0.5 %
GelTopical10 mg/mL
LotionTopical2 %
SwabTopical2 %
SwabTopical.5 %
CreamTopical20 mg/g
GelTopical20 mg/g
LotionTopical2 g/100mL
PlasterTopical.4 g/1
Kit; lotion; solutionTopical
ShampooTopical
PatchTopical4 mg/1
PlasterTopical.4 1/1
StripTopical4.42 mg/1
CreamTopical1 mg/20mg
RinseTopical2 g/100g
LiquidTopical.025 g/1
CreamTopical15 mg/mL
ConcentrateTopical2 g/100mL
SolutionTopical.013 mg/2.5mL
LiquidTopical.7 %
CreamTopical.02 g/mL
LiquidDental
GelTopical1 mL/100mL
GelTopical1 g/100mL
CreamTopical29 mL/100mL
GelTopical.008776 g/mL
LotionTopical1.8 mg/180mg
CreamTopical1 mg/100mL
ClothTopical.036 g/1
CreamTopical.02 g/1000mL
LotionTopical2 mg/100mL
LotionTopical1 mg/100mL
GelTopical5 mg/1000mL
SolutionTopical5 mg/1000mL
LiquidTopical2 mg/100mL
LotionTopical.5 mg/100mL
Lotion / shampooTopical.02 g/1000mL
SoapTopical1 g/100g
GelTopical.5 mg/100mL
CreamTopical1.5 g/100g
LiquidTopical0.5 %
LotionTopical0.5 %
SwabTopical0.5 %
GelTopical1.77 g/59mL
CreamTopical2.26 g/113g
CreamTopical1.1 g/56.7g
SoapTopical3 g/100g
ShampooTopical3 g/100g
CreamTopical2.5 g/100g
CreamTopical3 g/100mL
LiquidTopical1.8 g/100mL
CreamTopical17 g/100g
LiquidTopical2 mg/mL
SwabTopical20 mg/mL
SprayTopical4.8 mL/240mL
PatchTopical.04 g/40mL
StickTopical1 %
LiquidTopical2 mL/100mL
ShampooTopical.25 g/100mL
CreamTopical24 g/400g
LotionTopical24.84 mg/414mL
LotionTopical60 mg/mL
GelTopical1.2 g/60g
Aerosol, foamTopical6 g/100g
CreamTopical27.24 g/g
CreamTopical6 g/100g
CreamTopical60 mg/g
GelTopical.17 g/7g
GelTopical.21 g/1.25g
GelTopical60 mg/g
LiquidTopical.17 g/g
LiquidTopical.17 mg/9.8mL
LiquidTopical.17 g/9.8mL
LiquidTopical.17 mg/9.8g
LiquidTopical.17 mg/15mL
LiquidTopical.17 mg/151mL
LiquidTopical.17 g/9mL
LiquidTopical2 g/100g
LiquidTopical2.1 g/14.7mL
LiquidTopical260 mg/mL
LiquidTopical275 mg/mL
LotionTopical.5 g/60mL
LotionTopical6 mg/100mL
LotionTopical6 g/100mL
LotionTopical60 mg/g
PatchTopical40 mg/91
PatchTopical40 mg/241
PatchTopical40 mg/141
PatchTopical40 mg/181
PatchTopical40 mg/41
PatchTopical40 mg/61
PlasterTopical.4 g/1411
PlasterTopical.4 g/141
PlasterTopical40 mg/141
ShampooTopical2 g/100g
ShampooTopical6 mg/100mL
StripTopical40 mg/1
GelTopical.75 mg/150mL
SoapTopical3.5 %
LiquidTopical.02 mg/mL
LiquidIntravenous570 mg
GelTopical15 mg/mL
Aerosol, foamTopical3.88 g/70g
SoapTopical
LiquidTopical12 g/100mL
LiquidTopical30 mg/g
LiquidTopical17 %
GelTopical2 g/100mL
GelTopical8 g/100g
PasteTopical1 g/100g
Liquid; shampooTopical
ShampooTopical.03 g/mL
LiquidTopical.5 mL/100mL
CreamTopical20 mg/mL
GelTopical154 mg/30mL
CreamTopical1.8 %
LiquidTopical
LiquidTopical.6 g/100mL
LiquidTopical1.5 mg/100mL
RinseTopical.5 mL/100mL
LiquidTopical20 g/2mL
LiquidTopical5 g/2mL
LiquidTopical.5 mg/mL
LotionTopical15 mg/mL
LiquidTopical.2 g/g
KitTopical
GelTopical.5 g/100g
ClothTopical2 g/100g
LiquidTopical20 mg/1
SolutionTopical17 %
ShampooTopical18 mg/L
SoapTopical20 mg/mL
CreamTopical2.0 %
LiquidTopical.009506 g/100mL
CreamTopical.065 mg/13mL
EmulsionTopical.02 g/g
SoapTopical.02 g/mL
EmulsionTopical.01 g/mL
EmulsionTopical.02 mL/mL
EmulsionTopical.02 g/mL
EmulsionTopical.01 mL/mL
LiquidTopical2.2 %
SoapTopical.01 mL/mL
SoapTopical.02 mL/mL
SoapTopical.02 g/g
LiquidTopical1 g/100mL
LiquidTopical2 g/100mL
LiquidTopical.1 g/1
LiquidTopical.5 g/100mL
CreamTopical
ShampooTopical2 %
SuspensionTopical2 %
ShampooTopical3 %
OintmentTopical3 g/100g
StickTopical12 g/100g
StickTopical15 g/100g
LotionTopical1 g/100g
LotionTopical2 g/100g
OintmentTopical.14 g/28g
SprayTopical
ShampooTopical18 mg/mL
SolutionTopical
LiquidTopical.0024 mg/.12mg
PlasterTopical15 %
CreamTopical2 g/100mL
SolutionTopical285 mg/mL
GelTopical17 g/100g
PatchTopical.4 g/100g
LiquidTopical170 mg/mL
LiquidTopical17 mL/10mL
CreamTopical5 mg/mL
LotionTopical.5 mL/50mL
GelTopical1 mL/200mL
GelTopical.625 mL/125mL
LiquidTopical1 mL/200mL
SolutionTopical275 mg/mL
DiscTopical17.67 mg/1
LiquidTopical.25 g/100mL
LiquidTopical.15 g/100mL
SprayTopical15 mg/mL
EmulsionTopical1.2 g/120mL
PlasterTopical40 mL/1
GelTopical.17 g/g
LiquidTopical2.51 mL/14.78mL
GelTopical4 g/200g
SwabTopical1 g/100g
SwabTopical2 g/100g
SoapTopical.001 g/.1g
SoapTopical1 mg/100g
SolutionTopical280 mg/g
ShampooTopical10 g/325g
GelTopical5 mg/237mg
PlasterTopical; Transdermal40 g/1
PlasterTopical
PlasterTopical156 mg/1
LiquidTopical5.3 g/265mL
ClothTopical5 mg/mL
StickTopical1 g/100g
GelTopical1 mg/100mL
CreamTopical10 mg/mL
SolutionTopical2 mg/100mL
CreamTopical.47 mL/100mL
LiquidTopical.47 mL/100mL
GelTopical.47 mL/100mL
StickTopical20 mg/g
Prices
Unit descriptionCostUnit
Keralyt scalp complete kit67.8USD kit
Keralyt 6% Gel 100 gm Tube51.99USD tube
Keralyt 6% Gel 40 gm Tube49.99USD tube
Compound W 17% Liquid 9.3ml Bottle11.99USD bottle
Keralyt 3% Gel 28.4 gm Tube11.35USD tube
Sastid soap4.32USD each
Salicylic acid 6% gel1.14USD g
Salactic film solution0.74USD ml
Compound w pads0.5USD each
Keralyt 6% gel0.5USD g
Freezone corn-callus liquid0.42USD ml
Keralyt 3% gel0.39USD g
Salicylic acid 6% shampoo0.21USD ml
Ionil plus 2% shampoo0.05USD ml
Ionil t plus shampoo0.05USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)158 °CPhysProp
boiling point (°C)211 °C at 2.00E+01 mm HgPhysProp
water solubility2240 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.26HANSCH,C ET AL. (1995)
logS-1.82ADME Research, USCD
Caco2 permeability-4.79ADME Research, USCD
pKa2.97SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility11.3 mg/mLALOGPS
logP1.96ALOGPS
logP1.98ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.53 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity35.3 m3·mol-1ChemAxon
Polarizability12.81 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9756
Blood Brain Barrier+0.6165
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.734
P-glycoprotein inhibitor INon-inhibitor0.9815
P-glycoprotein inhibitor IINon-inhibitor0.9937
Renal organic cation transporterNon-inhibitor0.9167
CYP450 2C9 substrateNon-substrate0.7962
CYP450 2D6 substrateNon-substrate0.9233
CYP450 3A4 substrateNon-substrate0.766
CYP450 1A2 substrateNon-inhibitor0.9517
CYP450 2C9 inhibitorNon-inhibitor0.7984
CYP450 2D6 inhibitorNon-inhibitor0.9659
CYP450 2C19 inhibitorNon-inhibitor0.7644
CYP450 3A4 inhibitorNon-inhibitor0.8675
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8525
Ames testNon AMES toxic0.9829
CarcinogenicityNon-carcinogens0.8627
BiodegradationReady biodegradable0.8086
Rat acute toxicity2.2160 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9631
hERG inhibition (predictor II)Non-inhibitor0.9734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.17 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (2 TMS)GC-MSsplash10-014i-3890000000-62eae168a9d7ab3ada6f
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00du-9700000000-e1e2ee6b61d86c596403
GC-MS Spectrum - GC-MSGC-MSsplash10-014i-3890000000-62eae168a9d7ab3ada6f
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-014i-2960000000-1b6b46cbb2b643b71448
Mass Spectrum (Electron Ionization)MSsplash10-00du-9600000000-6d4a0ff2d48d814b5c54
MS/MS Spectrum - Quattro_QQQ 10V, NegativeLC-MS/MSsplash10-059j-9600000000-54545731fceee84be340
MS/MS Spectrum - Quattro_QQQ 25V, NegativeLC-MS/MSsplash10-00xu-9500000000-2f1c989b672669aaf083
MS/MS Spectrum - Quattro_QQQ 40V, NegativeLC-MS/MSsplash10-0gb9-9000000000-a0049e982e8ecd7ab730
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-000i-0900000000-f1e71df6894bcc8dda74
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-0006-9200000000-f9fd317c182ec7ca90dc
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-0006-9000000000-2b17aea4ee0ddd6321cf
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-0006-9000000000-320b7cd879b61439cf42
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-0006-9000000000-7d1b96d60026076a7ecc
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF , NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 10V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF , NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 10V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - DI-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9400000000-b0fb5458dfa73429b976
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9400000000-b0fb5458dfa73429b976
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9100000000-237ee14e8af5262c0dab
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9000000000-3ec5d7a9114e37b8af2a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9000000000-d8fdab29114453b10280
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9000000000-4a337e3639c9f42a9000
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9000000000-2deb0e843e099fdcea99
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00kf-9000000000-951b374b351c5534628a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-9000000000-4ea52d5aa4344a40c007
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-0900000000-f1e71df6894bcc8dda74
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-9200000000-65f3f297188dc07b53be
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-9000000000-2b17aea4ee0ddd6321cf
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-9000000000-320b7cd879b61439cf42
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-9000000000-7d1b96d60026076a7ecc
LC-MS/MS Spectrum - LC-ESI-TOF , negativeLC-MS/MSsplash10-000i-0900000000-f88c693bac9b89416a52
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0900000000-dd7c7e9bb99d16d9e3b3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0900000000-2106a18c58cc09ba35d2
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0900000000-79094eef5dfa59aa3723
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-1900000000-333f3c35ef30a1009fde
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-3900000000-1650d1f6c5415fb2e6c3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01b9-9700000000-e00d66b41e77653cb63f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-9100000000-37a9d14bd1eea4079faa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-9000000000-38a1383fd22f1277e48e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-9000000000-af5a2b43adf8dc36435f
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,1H] 2D NMR Spectrum2D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Salicylic acids
Alternative Parents
Benzoic acids / Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Salicylic acid / Benzoic acid / Benzoyl / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Vinylogous acid / Monocarboxylic acid or derivatives / Carboxylic acid / Carboxylic acid derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monohydroxybenzoic acid (CHEBI:16914)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Moon C, Ahn M, Jee Y, Heo S, Kim S, Kim H, Sim KB, Koh CS, Shin YG, Shin T: Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett. 2004 Feb 12;356(2):123-6. [PubMed:14746879]
  2. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793]
  3. Sun R, Carlson NG, Hemmert AC, Kishore BK: P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol. 2005 Sep;289(3):F585-92. Epub 2005 Apr 19. [PubMed:15840771]
  4. Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, Misirligil Z: Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005 Mar;42(2):127-31. [PubMed:15871445]
  5. Liu X, Lee TL, Wong PT: Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice. Anesth Analg. 2006 Jan;102(1):135-40. [PubMed:16368818]
  6. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5. [PubMed:5284360]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793]
  2. Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8. [PubMed:15070163]
  3. Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91. [PubMed:15106733]
  4. Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. [PubMed:15199473]
  5. Elvira C, Gallardo A, Lacroix N, Schacht E, San Roman J: Incorporation of salicylic acid derivatives to hydrophilic copolymer systems with biomedical applications. J Mater Sci Mater Med. 2001 Jun;12(6):535-42. [PubMed:15348270]
  6. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5. [PubMed:5284360]
  7. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS: Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes. 2007 Feb;56(2):337-45. [PubMed:17259377]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity
Specific Function
Converts progesterone to its inactive form, 20-alpha-dihydroxyprogesterone (20-alpha-OHP). In the liver and intestine, may have a role in the transport of bile. May have a role in monitoring the in...
Gene Name
AKR1C1
Uniprot ID
Q04828
Uniprot Name
Aldo-keto reductase family 1 member C1
Molecular Weight
36788.02 Da
References
  1. Dhagat U, Carbone V, Chung RP, Matsunaga T, Endo S, Hara A, El-Kabbani O: A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase. Med Chem. 2007 Nov;3(6):546-50. [PubMed:18045204]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Other/unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312]
  2. Xiao HR, Sheng LQ, Shi CH, Xu XL, Xie YS, Liu QL: [Fluorescence study on the interaction of salicylic acid and bovine serum albumin]. Guang Pu Xue Yu Guang Pu Fen Xi. 2004 Jan;24(1):78-81. [PubMed:15768982]
  3. Yin T, Wei W, Yang L, Liu K, Gao X: Kinetics parameter estimation for the binding process of salicylic acid to human serum albumin (HSA) with capacitive sensing technique. J Biochem Biophys Methods. 2007 Jun 10;70(4):587-93. Epub 2007 Jan 27. [PubMed:17320187]
  4. Yu T, Tao Z: [Fluorescence study on the interaction of salicylic acid and human serum albumin]. Guang Pu Xue Yu Guang Pu Fen Xi. 1999 Jun;19(3):453-5. [PubMed:15819089]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Cihlar T, Ho ES: Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem. 2000 Jul 15;283(1):49-55. [PubMed:10929807]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  3. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739]
  4. Uwai Y, Saito H, Inui K: Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol. 2000 Dec 1;409(1):31-6. [PubMed:11099697]
  5. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Not Available
Gene Name
SLC22A10
Uniprot ID
Q63ZE4
Uniprot Name
Solute carrier family 22 member 10
Molecular Weight
60256.57 Da
References
  1. Youngblood GL, Sweet DH: Identification and functional assessment of the novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney. Am J Physiol Renal Physiol. 2004 Aug;287(2):F236-44. Epub 2004 Apr 6. [PubMed:15068970]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  3. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y: Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23. Epub 2005 Jan 7. [PubMed:15640378]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Symporter activity
Specific Function
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucin...
Gene Name
SLC16A1
Uniprot ID
P53985
Uniprot Name
Monocarboxylate transporter 1
Molecular Weight
53943.685 Da
References
  1. Tamai I, Sai Y, Ono A, Kido Y, Yabuuchi H, Takanaga H, Satoh E, Ogihara T, Amano O, Izeki S, Tsuji A: Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J Pharm Pharmacol. 1999 Oct;51(10):1113-21. [PubMed:10579682]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T: Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14. [PubMed:12065749]
  2. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585]
  3. Morita N, Kusuhara H, Sekine T, Endou H, Sugiyama Y: Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1179-84. [PubMed:11504818]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18